Previous 10 | Next 10 |
2023-05-09 13:22:40 ET Gainers: TScan Therapeutics ( TCRX ) +124% . Shengfeng Development Limited ( SFWL ) +102% . Mobiquity Technologies ( MOBQ ) +68% . ClearOne ( CLRO ) +62% . U.S. GoldMining ( USGOW ) +57% . Novavax ( N...
2023-05-09 10:00:33 ET Gainers: TScan Therapeutics ( TCRX ) +151% . Ensysce Biosciences ( ENSC ) +60% . Novavax ( NVAX ) +36% . Y-mAbs Therapeutics ( YMAB ) +30% . Longeveron ( LGVN ) +26% . Losers: Enanta Pharmaceuti...
Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in May:...
2023-05-08 18:48:06 ET Enanta Pharmaceuticals, Inc. (ENTA) Q2 2023 Earnings Conference Call May 08, 2023 04:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President & Chief Executive Officer Scott Rottinghaus - Chief Medical Offi...
2023-05-08 18:03:40 ET Gainers: Oportun Financial ( OPRT ) +23% . EverQuote ( EVER ) +22% . Tactile Systems Technology ( TCMD ) +17% . Rover Group ( ROVR ) +14% . Y-mAbs Therapeutics ( YMAB ) +13% . Losers: Enanta P...
2023-05-08 17:48:08 ET Enanta Pharmaceuticals ( NASDAQ: ENTA ) is down 21% in after-hours trading after its fiscal 2023 Q2 results missed on the top line. Revenue of $17.8M was a ~5% year-over-year decline. Consensus was $19.06M. Enanta's ( ENTA ) net loss widene...
2023-05-08 17:35:58 ET Enanta Pharma ( NASDAQ: ENTA ) is scheduled to announce Q2 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is -$1.93 (-18.4% Y/Y) and the consensus Revenue Estimate is $19.06M (+1.8% Y/Y). Over the last 1 year...
2023-05-08 16:07:41 ET Enanta Pharma press release ( NASDAQ: ENTA ): FQ2 GAAP EPS of -$1.79 beats by $0.13 . Revenue of $17.8M (-4.8% Y/Y) misses by $1.26M . For further details see: Enanta Pharma GAAP EPS of -$1.79 beats by $0.13, revenue of $17.8M misse...
Study Met Primary Endpoints of Safety and Tolerability Dose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to Placebo, Achieving Statistical Significance as Early as One Day After First Dose No Difference in Viral Load Reduction; Rapid Declin...
Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor in Development as an Oral, Once-Daily Treatment for COVID-19 Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET ® /MAVIRET ® Royalties for an Up...
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strate...
2024-05-10 16:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...